Protox(TM) Therapeutics Inc. (TSX-V:PRX) today announced interim results from its ongoing Phase I clinical trial evaluating PRX302 in patients with localized, recurrent prostate cancer. The findings to date indicate that PRX302 is well tolerated and shows encouraging signs of therapeutic activity following a single intra-prostatic injection.

“First and foremost, we are pleased with the safety profile of PRX302 thus far,” said Dr. Fahar Merchant, President and Chief Executive Officer of Protox. “We have now reached the mid-point of this study with no significant safety concerns and with signs of a therapeutic effect, even at these low dosages. These data, although preliminary, support our expectations for this treatment, both in prostate cancer and in our approved BPH trial planned to commence this year.”

The Phase I study is being led by Dr. Scott Coffield at Scott and White Memorial Hospital, with other participating sites including M. D. Anderson Cancer Center, Urology San Antonio and the University of Vermont. This trial is intended to examine the safety, tolerability and therapeutic activity of PRX302 in patients with localized recurrent prostate cancer who show signs of disease progression as evidenced by rising levels of PSA.

Using well-established, image-guided brachytherapy techniques, PRX302 was injected directly into the prostate. To date 12 patients at four clinical trial sites have been treated, with each new cohort of 3 patients receiving a higher dose once safety of the drug is established in the previous cohort. The dose has escalated 20-fold since the study commenced.

No safety issues relating to PRX302 treatment have been encountered to date. PRX302 was well-tolerated in all patients and there has been no evidence of systemic toxicity. No serious adverse events were reported relating to PRX302 and most other adverse events reported were those typically associated with the injection procedure, rating no higher than Grade 1 (mild) or Grade 2 (moderate) on the National Cancer Institute’s 5-stage grading scale.

Early assessment of potential therapeutic activity was determined by measuring PSA (prostate specific antigen) levels throughout the study and conducting prostate biopsies at 30 days post-treatment. PSA is one of the most widely recognized disease markers in oncology and levels of PSA in the blood are used in the diagnosis of prostate cancer, monitoring cancer progression and tracking patient responses to its treatment.

Results show that eight of nine patients for whom 90-day data are available reported a decrease in PSA levels compared to baseline during at least one of the 14-, 30-, 60- or 90-day follow-up intervals. For six out of the nine patients, reductions in PSA levels continue to be observed through day 90 or longer, with PSA levels falling by 6% to 42% compared to baseline.

A comparison of prostate biopsies taken at baseline and at 30 days post-treatment shows that 8 of the 10 patients for whom data are available had a decrease in cancer-positive biopsies. The average decrease was 36% with four patients showing a 50% or greater reduction, including two who showed a 100% reduction.

“Patient responses have been encouraging at these low doses with few adverse events and observable decreases in cancer-positive biopsies and PSA levels,” said the study’s lead investigator, Dr. Scott Coffield of Scott & White Memorial Hospital. “As the dose is escalated to levels found to produce substantial prostatic destruction in relevant pre-clinical models, we expect more of the patients will manifest absence of cancer on post-therapy biopsy with concomitant decrease in PSA levels.”

The company expects to complete the study by mid-year and begin planning for Phase II to commence by year-end.

Conference call
Protox will host a conference call and live webcast today at 10:00 a.m. E.T. to discuss these interim results. To access the conference call by telephone, dial 416-644-3414 or 1-800-733-7560. Please connect approximately ten minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until February 20, 2007 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21216654 followed by the number sign.

A live audio webcast of the conference call will be available at www.protoxtherapeutics.com. Please connect at least ten minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 30 days.

About Prostate Cancer
Prostate cancer is a leading cause of cancer death in North American men. One in every six men is diagnosed with prostate cancer during their lifetime. The American Cancer Society estimates that during 2006 approximately 234,500 new cases of prostate cancer will be diagnosed and over 27,000 men will die from the disease in the U.S. Current treatment options for localized prostate cancer include surgery and radiation therapy. Serious side effects are associated with these therapies including erectile dysfunction, incontinence, urinary dysfunction and bowel problems. Current therapies to treat locally recurrent prostate cancer are associated with significant side effects.

About PRX302
PRX302 is the lead drug in the company’s PORxin(TM) technology platform. PORxin drugs are pro-drugs that are activated by specific proteases produced at elevated levels on the surface of target cells. PRX302 has been generated by engineering the naturally occurring toxin proaerolysin to create a potent anti-cancer agent with a distinct mode of action. The drug has been engineered so that it is activated by prostate-specific antigen (PSA), an enzyme that is overproduced in patients suffering from prostate cancer and enlarged prostate (benign prostatic hyperplasia or BPH). Once activated, the drug punches holes in the cells causing the contents to leak out and ultimately cell death.

About Protox
Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin(TM) and PORxin(TM), and currently has three clinical programs in development. A Phase IIa clinical trial into the use of PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a Phase I trial has been completed for PRX321 to treat patients with renal cell carcinoma and non-small cell lung cancer. Patient enrolment is underway for a Phase I clinical study into the use of PRX302 (PORxin) to treat localized prostate cancer. PRX302 has also been approved by Health Canada to commence a Phase I clinical study for the treatment of benign prostatic hyperplasia.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox’ current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

Anthony Boone, Director, Investor Relations and Corporate Communications, Protox Therapeutics
T: (604) 688-4369
C: (778) 996-4369
aboone@protoxtherapeutics.com;

Michael Moore, Investor Relations, Equicom Group,
(416) 815-0700 x 241
mmoore@equicomgroup.com

1) When my investment gets back up to what I paid, get me out. This is surely a big mistake. That stock has absolutely no idea that you’re waiting for it to go up so that you can sell.

2) The stock is selling at $3.00 a share. How much can I lose? $3 multiplied by the number of shares. Oh yeah, don’t forget to add in commission.

3) I want to buy shares of XYZ Company. Three years ago, they were selling at $60; now the stock selling at $5. You can actually make a lot of money investing in good companies when their stocks are out of favor (go to dictionary – look up: “Warren Buffett”). You cannot make money buying junk just because it’s cheap. (Same dictionary – lookup “cheap junk”). If this creates confusion – please see item 2.

4) The stock is up 10 % this past month. It’s too high, I can’t buy it now. Have you ever heard of a long-term uptrend? Just because you missed the bottom doesn’t mean you missed the boat. I’ve heard that the shortest time measurable by man is the time between when it’s too soon to buy a stock and when it’s too late.

5) I paid $60 for that stock 3 years ago. Today it’s selling at $4. I can’t afford to sell. I don’t want to lose so much. I’m just guessing here, but did you say the same thing at $30? $20?

6) I bought the stock at $10 and now it’s $35. I have too much profit. I can’t sell here. I don’t want to pay so much in taxes. My wish for everybody is that next year you have more than twice the profits and that you have to pay twice as much in taxes.

7) I never sell an investment at a loss. I’m a long-term investor. Eventually, they always come back. Ever heard of ENRON? Pan American Airlines? Polaroid? Penn Central Railroad? If I were to be your advisor for the next 20 years, I GUARANTEE you that you will have losses. Losses are a very important part of a successful investment program. Since the perfect human hasn’t been created yet, the perfect advisor hasn’t been created yet. Expect to have some losses and plan accordingly.

8) Sell my utilities; buy DOTCOMS. Stock brokers heard this, a lot, just a few short years ago. Every up cycle investment advisors are instructed to sell safe, but dull investments and buy something with sex appeal that’s moving. The worst possible thing has happened – one of the clients’ friends or acquaintances is making more money than they are. It’s the CINDERELLA story. They’ll look great for a short time. Then, the clock strikes “OVER” and their limo turns back into a pumpkin.

9) I know as much about the stock market as any broker. What would you think of me if I came to your place of business and told you that I know as much about your business as you do? Can you outperform a professional in the short run? Absolutely. You would never say this to your doctor, lawyer or accountant. You wouldn’t even say that to your butcher or your barber. Stock market investing is the only profession where the amateurs think they know as much as the professionals because they might have picked a winner at one time.

10) That total stranger made the investment sound like such a great idea. Of course he did. That’s his job. Do you remember your mother telling you “Don’t talk to strangers.”? When was the last time you ran with scissors? If you develop the practice of giving your money to strangers, sooner or later, you will come to harm. Or, as Al Capone used to say “Anybody found sleeping in the trunk of a car, deserves to be shot.”

Gary Wollin is a Warren Buffet style investment advisor with 45+ years of Wall Street experience. He has been regularly featured in The Wall Street Journal, New York Times and many other publications around the world. He writes and speaks on sales, customer loyalty, and the stock market. For more information, please visit http://www.garywollin.com

December 4, 2006
TSX Venture: CNU

NEWS RELEASE
$6,750,000
PRIVATE PLACEMENT

The Company announces that it has engaged Bolder Investment Partners as its lead Agent to conduct, on a commercially reasonable efforts basis, a private placement of up to 27,000,000 Units at a price of $0.25 per Unit for gross proceeds of $6,750,000. Each Unit will consist of one common share and one-half of one non-transferable share purchase warrant. Each whole warrant will entitle the holder to purchase an additional common share of the Company at a price of $0.30 per share for a period of one year.

A cash commission of 7.5% of the total proceeds raised is payable to the Agent, which the Agent may elect to be paid in Units at the same price and having the same terms as the Units offered in the private placement. The Agent will also receive agent’s warrants entitling them to purchase common shares totaling up to 10% of the number of Units issued under the private placement. Each agent’s warrant will have the same terms as the warrants issued as part of the Units. The Company will also offer a 1.5% commission to any individuals raising funds other than the Agent.

This placement is subject to the approval of the TSX Venture Exchange Inc. The proceeds of the private placement will be used primarily for exploration, drilling and tunneling on the Company’s past-producing, Natividad Mine property. In addition, the Company will use the funds raised to maintain its 24% stake in the joint venture agreement on the San Jose – Taviche properties with Fortuna Silver Mines Ltd. (see our news release dated November 24, 2006) as well as for general working capital.

ON BEHALF OF THE BOARD OF DIRECTORS

CONTINUUM RESOURCES LTD.
Per: “GREIG HUTTON”
Greig Hutton, President

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Links to Independant Research and News Releases:
Fundamental Research Corporation – Analyst Report
Monday, November 21, 2006

Continuum and Fortuna complete acquisition of San Jose Ag-Au Project, Mexico
Monday, November 27, 2006

Vancouver, British Columbia: Bell Resources Corporation (the “Company” or “Bell”) is pleased to announce partial drillcore assays from the Phase I drill program on its Sombrero Butte Project, located in the Copper Creek district, Pinal County, Arizona. The intent of the current drilling program is to test a cluster of nearly twenty breccia pipes, several of which contain high grade copper as chalcocite, bornite, and chalcopyrite. These early assays support the Company’s belief that copper mineralization in the breccia pipes may be related to an underlying porphyry copper deposit.

Highlights:

* Extensive copper intersections including 48 meters (158 feet) of 1.06%

* Initial drilling has intersected porphyry intrusions in drill hole SB-02

* Based on preliminary results a second more extensive program has been approved to immediately follow the Phase I drill program

All three drillholes were collared from a common drill pad at various angles to test three distinct breccia pipe targets. Drillhole SB-01 was drilled in a southeasterly direction at an inclination of 45° to test the shallow parts of the Magna and Sunset breccia pipes. The oxidized and leached tops of both of these breccia pipes were intersected by the drillhole.

Strong evidence of prior primary copper mineralization in the form of earthy hematite led to the redrilling of the Magna breccia pipe in SB-02, which was also drilled in a southeasterly direction but at an inclination of 82°. This drillhole cut the Magna breccia and demonstrated a significant interval of supergene copper (chrysocolla and chalcocite) enrichment beneath the leached capping. Porphyry intrusions formed the matrix of the breccia in several intervals, reinforcing the concept of a genetic link between the breccia-related mineralization and a possible underlying porphyry copper system.

Drillhole SB-03 was drilled in a northeasterly direction at an inclination of 80°. This hole tested a third target, the Campstool breccia pipe. The drillhole intersected two intervals of significant copper mineralization in the form of chrysocolla, native copper, chalcocite, bornite, and chalcopyrite, accompanied by tourmaline, specular hematite, amythest, and rhodochrosite.

After completion of the drilling which is currently underway to test the Maverick breccia pipe, the drill will move to a new drill site to test the supergene enriched portions of the Sunset breccia pipe. Based on these preliminary results the program has been doubled in size to 10,000 feet of coring. The Company plans to complete additional drillholes on the Victors and Saguaro breccia pipes in the next drilling campaign. This drilling is expected to extend into the 1st Quarter of 2007.

The management of Bell has significant experience in North and South American porphyry copper systems and the relationship between breccias and porphyry copper deposits. Additionally, W. Glen Zinn and Dr. Tim Marsh have extensive experience in the Copper Creek district where previously they were responsible for the identification of a significant copper resource.

“Based on our knowledge and experience in the Copper Creek District we are very excited by these excellent early results and the strong indications they provide of an underlying copper porphyry system”. – W. Glen Zinn, President & C.E.O.

Sampling was conducted under the direct supervision of Amy Eichenlaub, B.Sc., Project Geologist, and Rex Evatt III, B.Sc., geological consultant to the Company. Samples are kept in a locked container and are delivered in person to the laboratory by Ms. Eichenlaub. Control samples, including field blanks, copper standards, and duplicate splits of core were inserted into the sample stream at an average rate of one control sample per seven unknowns.

For the purposes of this news release, the Company’s Vice President of Exploration, Timothy Marsh, P.E., PhD, is the Qualified Person.

Sombrero Butte Project

The Sombrero Butte Project is located in Pinal County, Arizona. The project represents the first consolidation of these claims since they were mined back in 1920. The Sombrero Butte Project constitutes a significant opportunity to quickly delineate high grade copper breccia resources. A transition with depth from the high grade breccia environment to a larger tonnage porphyry copper system is also expected at Sombrero Butte.

Bell Resources is focused on the exploration and development of a diversified portfolio of North American base metal projects with the most advanced being the past producing Granduc Mine. All projects will be advanced along a path toward potential production enabling Bell Resources to make the transition from explorer to producer.

On Behalf of the Board of Directors of
Bell Resources Corporation

“W. Glen Zinn”

W. Glen Zinn, CEO, President & Director

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Forward-looking statements in this release are made pursuant to the ‘safe harbor’ provisions of the Private Securities Litigation Reform act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties.

October 16th 2006 marks the official launch of a stock market trading and stock investing resource, Tradeopolis.com. A site featuring online stock trading information on penny stocks to mutual funds publicly traded on the Toronto Stock Exchange and TSX Venture Exchange.

Tradeopolis.com is a stock market trading and stock investing website built on honesty and integrity in an industry swarming with deception and deceit. A website focused on providing an interactive and educational resource for the stock market investor and Canadian public companies to interact and educate by providing the most current investment opportunities and educational investment articles.

Tradeopolis.com posts daily articles on stock market trading and stock investing, and features company information and press releases on Toronto Stock Exchange and TSX Venture Exchange companies.

Tradeopolis.com utilizes a blog format for enhanced site interaction and provides a space for TSX and TSX Venture Exchange companies to post news releases on the front page of the site. By having a daily news release exclusively featured front and centre, visitors are easily introduced to these new stock investing opportunities.

In an effort to provide investors and those new to investing with a resource of information, Tradeopolis.com also features a growing resource of educational information on stock market trading or stock investing as well as investing in mutual funds, penny stocks and general investing basics.

Through the site, readers will be able to access press releases, post comments on existing and previous articles, access a stock ticker, stock quotes, news feeds, and relevant investment articles written both by Tradeopolis contributors and reputable resources.

Tradeopolis.com has been designed with new Internet technologies in mind. Through the use of RSS (Real Simple Syndication) readers can subscribe to RSS feeds through newsreaders. In addition, this technology also allows other websites to syndicate Tradeopolis content, further increasing the readership of news releases and visitors to the site, thereby increasing the value of services to its customers.

The vision of Tradeopolis.com is to build a community that grows and thrives on customer input, what a concept, putting the customer first.

Contact Information:
Tradeopolis.com
Phone: (250) 434-4509
Email: info@tradeopolis.com

Bombardier Transportation and its local partner Hartasuma Sdn Bhd have signed a contract with Syarikat Prasarana Negara Berhad (SPNB) for an initial 88 advanced rapid transit (ART) MK II cars to be used on the Kelana Jaya Line in Kuala Lumpur, Malaysia. The contract is valued at approximately $210 million US (167 million euros) with Bombardier’s share valued at approximately $147 million US (117 million euros). The agreement includes options for 52 additional cars. Should all options be exercised, the entire contract would total 140 cars and be valued at approximately $320 million US (255 million euros).

The fully automated, driverless Kelana Jaya Line began operation in 1998 and was built by a Bombardier-led consortium that included Bombardier and SNC Lavalin. Today, the line links western and eastern suburbs to Kuala Lumpur’s downtown. At 29 km, the Kelana Jaya Line is the longest fully automated, driverless transit system in Asia. The line currently uses 70 Bombardier-built ART MK II vehicles. SPNB’s order for new vehicles will expand the line’s passenger carrying capability. The line is currently operating at maximum capacity.

“Our mission is to provide a highly integrated and efficient public transport infrastructure that will bring positive economic contribution through enhanced public mobility and will improve the overall quality of life for the citizens of Kuala Lumpur,” said Encik Shaipudin Shah Harun, Executive Director and Chief Executive Officer of SPNB. “That is why we once again rely on Bombardier technology to improve the service on the Kelana Jaya Line.”

The cars will be manufactured at Bombardier Transportation production facilities in North America with final assembly in Malaysia through the local partner, which is a major player in the Malaysian rail industry. Delivery of the cars is expected to take place between September 2008 and June 2010.

Bombardier is the world leader in designing and supplying automated rapid transit systems, monorails and people movers for urban and airport applications. The expansion to the existing 29-km Kelana Jaya line will use Bombardier’s Linear-Induction-Motor (LIM) propulsion, successfully deployed on the Vancouver SkyTrain(i), the longest driverless system in the world; New York City’s 13-km AirTrain(i) JFK, where Bombardier is providing up to 15 years of operations and maintenance services; as well as the Scarborough RT system (Toronto, Canada) and the Detroit Downtown People Mover, USA. Bombardier is also managing other ART projects in Asia; one recently announced for the Beijing Airport Link in China and one already under construction for Yongin City in South Korea. With over 70 years of combined system operation, ART technology offers unprecedented reliability.

“We are very proud of the cars and system already delivered to Kuala Lumpur,” said William Spurr, President, Bombardier Transportation, North America. “This order allows us to build on a long-standing relationship with our customer SPNB. It confirms once again the success of Bombardier’s LIM technology, developed in Ontario, Canada, for applications around the world.”

“Hartasuma is proud to be associated with a world leader like Bombardier. This partnership will enhance the local rail industry,” said Datuk Ravindran Menon, Group Executive Director, Hartasuma Sdn Bhd .

Bombardier Transportation has its global headquarters in Berlin, Germany, with a presence in over 60 countries. It has an installed base of approximately 97,000 vehicles worldwide. The company offers the broadest product portfolio and is recognized as the leader in the global rail sector.

(i) Bombardier SkyTrain and AirTrain are trademarks of Bombardier Inc. or its subsidiaries

About Bombardier
A world-leading manufacturer of innovative transportation solutions, from regional aircraft and business jets to rail transportation equipment, Bombardier Inc. is a global corporation headquartered in Canada. Its revenues for the fiscal year ended Jan. 31, 2006 were $14.7 billion US and its shares are traded on the Toronto Stock Exchange (BBD). News and information are available at www.bombardier.com.

Contact:

Bombardier Transportation
David Slack
Director, Communications, North America
(450) 441-3190
Website: http://www.bombardier.com

Ambrilia to receive an upfront payment of $US 17 million and potential milestones of up to $US 215 million.

Ambrilia Biopharma Inc. (TSX:AMB.TO – News), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, and Merck & Co., Inc., one of the world’s leading pharmaceutical companies, announced today that Ambrilia has entered into an exclusive licensing agreement granting Merck – through an affiliate – the worldwide rights to Ambrilia’s HIV/AIDS protease inhibitor (PI) program.

Under the terms of this agreement, Ambrilia grants Merck the exclusive worldwide rights to its lead compound, PPL-100, which has completed a Phase I single-dose pharmacokinetic study and is currently in a Phase I repeat dose pharmacokinetic study. In return Ambrilia receives an upfront licensing fee of $US 17 million on signing and is eligible for cash payments totaling up to $US 215 million upon successful completion of development, clinical, regulatory and sales milestones, and royalties on all future product sales. The first of the milestone payments ($US 3 million) will be based on the successful completion of a Phase I repeat dose pharmacokinetic study, the results of which are expected in late November. Once the Phase I repeat dose pharmacokinetic study is completed, Merck will assume all subsequent development costs related to PPL-100.

Ambrilia also stands to receive significant additional milestone-based cash payments and royalties on the future development and commercialization of each back-up compound and/or related compounds developed by Merck and which fall within the scope of the Ambrilia PI program.

“We are very pleased to partner on PPL-100 with Merck, a company that has been a leader in anti-HIV drug development, and are confident that Merck will successfully advance the development of PPL-100,” said Hans J. Mader, President and Chief Executive Officer of Ambrilia. “This agreement is a significant milestone for Ambrilia; an influx of potentially over $CDN 22 million in 2006 allows the Company to be much stronger financially and provides us with the opportunity to allocate the necessary resources to further progress the development of our other technologies and product candidates.”

“Merck has been a world leader in the fight against HIV/AIDS for two decades, and this agreement is a further demonstration of our continuing commitment to this field of medicine,” said Merv Turner, Ph.D., Senior Vice President, Worldwide Licensing and External Research. “PPL-100 and Ambrilia’s Protease Inhibitor Program represent a potentially significant advancement for patients and physicians in the treatment of HIV/AIDS.”

CONFERENCE CALL INFORMATION

Ambrilia will be hosting a conference call on October 12, 2006 at 9:30 a.m. ET, to discuss its licensing agreement with Merck & Co., Inc. Interested parties may access the conference call by way of telephone or webcast. The numbers to access the conference call are 1(866) 250-4910 (toll free) or 1(416) 644-3423 (local). The webcast will be available at: www.ambrilia.com, Investors section, conference calls and webcasts, and will be archived for 365 days. A replay of the call will be available and the numbers to access the replay are 1(416) 640-1917 (local) or 1(877) 289-8525 (toll free) with access code 21206250. The replay will be available starting at 11:30 a.m., October 12, until 11:59 p.m., October 19.

ABOUT PROTEASE INHIBITORS

Protease Inhibitors (PIs) are a key component to the current HIV standard of care, the Highly Active Anti-Retroviral Treatment (HAART) consisting of a cocktail of HIV medicines. Unfortunately, many PIs are associated with side effects, a high pill burden and, as it is the case with all anti-HIV drugs, the development of viral resistance. In addition, the majority of PIs are administered in combination with a small dose of ritonavir, another protease inhibitor that is often used to increase, or boost, the amount of available drug in the system, but which also has the potential to increase adverse events. More than ever, there is a pressing need for better tolerated, more convenient and effective PIs.

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc. (TSX:AMB.TO – News) is a biopharmaceutical company developing innovative and proprietary early- to mid-stage therapeutics in the fields of oncology and infectious diseases. Ambrilia’s product portfolio includes an anti-cancer therapeutic peptide (PCK3145), a novel anti-cancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the first of which is late-stage and value-added, and promising anti-HIV treatments (PPL-100, Anti-HIV Peptides, Integrase Inhibitor Program). Ambrilia’s head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company’s web site: www.ambrilia.com

Ambrilia Forward-looking statement

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company’s filings. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia’s products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia’s views to change, Ambrilia specifically disclaims any obligation to update these forward-looking statements.

ABOUT MERCK & CO., INC

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit: www.merck.com

Merck Forward-Looking Statement

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck’s business, particularly those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K, which the company incorporates by reference.

Contact:

Contacts:
Ambrilia Biopharma Inc.
Julie M. Thibodeau, Director, Communications
514-751-2003 ext 235
jthibodeau@ambrilia.com
ir@ambrilia.com

http://www.ambrilia.com

Merck & Co., Inc.
Media: Janet Skidmore
Director, Media Relations
267-305-7715
janet_skidmore@merck.com

Merck & Co., Inc.
Investors: Graeme Bell
Senior Director, Investor Relations
908-423-5185
graeme_bell@merck.com

Source: Ambrilia Biopharma Inc.

CV Technologies Inc. (TSX:CVQ) – maker of COLD-fXTM – today provided an update to the business, scientific and investment communities.

U.S. Launch of COLD-fX
COLD-fX is being officially launched in the United States today and will be distributed by most of the leading pharmacy chains in the U.S. in their cough and cold section.

Hockey legend and COLD-fX celebrity spokesman Mark Messier, and CV Technologies’ President and CEO & Chief Scientific Officer, Dr. Jacqueline Shan, will be part of a public awareness campaign this week which will include TV, radio, newspaper and magazine interviews.

The U.S. marketing campaign involves advertising in leading newspapers and radio stations in major metropolitan centres along with promotions with the National Hockey League® under a new partnership with the league and its players association.

Included in pre-launch activities were national advertisements in USA Today and sponsorship of the 2006-2007 NHL season launch party in New York.

Medical, Industry Publications and Initiatives
COLD-fX will be included in the 2007 issue of the Physicians Desk Reference, used by a majority of the 800,000 American doctors and commonly found in hospitals and pharmacies in the U.S. Specific information on COLD-fX has already been directly mailed to pharmacists and physicians as an addendum to the 2007 companion book: Physicians Desk Reference for Nonprescription Drugs, Dietary Supplements and Herbs. This publication references the supporting clinical trials and scientific research on COLD-fX and will assist greatly in creating awareness among medical professionals.

The Company is exploring opportunities to conduct research collaborations with leading U.S. medical organizations as part of the campaign to further generate support and COLD-fX awareness in the health care community.

About CV Technologies Inc.

CV Technologies, founded in 1992, is a global leader in the development and commercialization of naturally derived, evidence based, clinically tested medicines for disease prevention and health maintenance. The Company’s lead product – COLD-fXTM – the top selling cold and flu remedy in Canada according to ACNielsen (52 weeks ending January 21, 2006), strengthens the immune system and is widely used as a leading over the counter remedy (OTC) for preventing and relieving cold and flu infections. In the U.S. it is marketed as an immune enhancing dietary supplement. COLD-fXTM , with its unique and patented mechanism of action was standardized according to the Company’s ChemBioPrint (CBP) Process. The CBP process precisely identifies the chemical profile and biological activity of multi-active compounds in evidence-based natural therapeutics. The CBP process also provides a manufacturing protocol that ensures each batch of the final product delivers verifiable and provable health benefits. All international patents and trademarks are held by fX LifeSciences International GmbH. COLD-fXTM is distributed and sold in the U.S. by COLD-fX Pharmaceuticals (USA) Inc. Both companies are wholly-owned subsidiaries of CV Technologies.

This news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results or events to differ materially from the results or events predicted in this discussion, including those comments predicting the timing and/or initiation of clinical trials, clinical trial results and associated regulatory clearances, entry and timing of entry into the U.S. market and the potential success of such initiatives. Factors which could cause actual results or events to differ include, but are not limited to: the impact of competition; consumer confidence and spending levels; general economic conditions; interest and currency exchange rates; unseasonable weather patterns; the cost and availability of capital; the cost and availability of grants/funding; product development and the risk that clinical trials may not demonstrate the safety and efficacy required to satisfy the regulatory authorities. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct and that the results, performance or achievements expressed in, or implied by, forward-looking statements within this disclosure will occur, or if they do, that any benefits may be derived from them. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. The Company assumes no duty to update this disclosure.

FOR FURTHER INFORMATION PLEASE CONTACT:
Media Contact:
CV Technologies Inc.
Warren Michaels
Vice President, Communications
(780) 432-0022
Email: warren.michaels@cvtechnologies.com

or

Investor Contact:
CV Technologies Inc.
Jane Tulloch, Director, Investor Relations
(780) 577-3724
Email: jane.tulloch@cvtechnologies.com
Website: www.cvtechnologies.com / www.coldfx.com

MagForestry Inc., (“MagForestry” or the “Company”) a division of MagIndustries Corp. (TSX VENTURE:MAA – News) announced today that it is now in receipt of TSX Venture Exchange approval in respect of the Company’s previously announced (see press release dated May 9, 2006) acquisition of the balance of the 45% of Chartwell Carbon Technologies (“Chartwell”) that it does not already own. Chartwell owns 100% of the shares of Eucalyptus Fibre Congo S.A. (“EFC”) (EFC is the lessee of a 68,000 hectare eucalyptus forestry plantation).

To accomplish this acquisition, MagIndustries Corp. entered into a share purchase agreement (“SPA”) with Adwell Holdings Limited, A. B. Swart and the Estate of Johan Kruger (the “Vendors”) to acquire the remaining 45% of the issued and outstanding shares of Chartwell, for consideration to be satisfied through the issuance of 3,500,000 common shares of MagIndustries and 1,000,000 common share purchase warrants, with each warrant entitling the holder to acquire one common share of MagIndustries at an exercise price of US$1.10 per share at any time until the 24 month anniversary of the issuance of the warrants. The above terms were negotiated in January 2006.

The MagIndustries Corp. shares to be issued as consideration for the purchase of the Chartwell shares are subject to a one year hold period which commenced in June 2006. Thereafter any transfer will be subject to a right of first refusal in favour of MagIndustries, with such right continuing for so long as both Mr. William Burton, MagIndustries’ President and Chief Executive Officer and Mr. Stephane Rigny, MagIndustries’ Executive Vice President remain officers of MagIndustries and holders of at least 2,000,000 common shares of MagIndustries.

MagIndustries had previously entered into a $2,000,000 convertible loan agreement (see press release dated July 11, 2005) with Chartwell which entitled MagIndustries to acquire 55% of the issued Chartwell share capital. This acquisition was concluded immediately following execution of the Shareholders’ Agreement by and between MagIndustries Corp. and the Vendors on October 24, 2005. Upon completion of the current transaction, MagForestry will control 100% of the issued share capital of Chartwell.

About Eucalyptus Fibre Congo SA

EFC leases a 68,000 hectare eucalyptus plantation (of which 20,000 hectares is presently unplanted), the majority of which overlies MagIndustries’ magnesium and potash mineral lease in the Pointe-Noire area of the Republic of Congo. In addition to being a world class renewable, sustainable forestry plantation, control of EFC secures long term land rights for MagMining’s brine well mining field, MagMinerals’ potash plant and MagMetals’ magnesium smelter.

Principally established by a division of Shell Oil International, Shell Renewables, between 1991 and 2001, this existing and well established forestry operation is based on the planting and harvesting of extremely fast-growing varieties of eucalyptus trees. Shell invested approximately $40 million and commercialized the operation initially for log sales. Shell’s long term strategy was to establish a renewable, sustainable high-yield source of biomass for future energy generation. EFC currently holds an exclusive 50 year forestry concession agreement with the Government of The Republic of Congo, which is renewable by EFC for an additional 21 years.

EFC is also a 33% partner of UR2PI, a research facility based in Pointe-Noire which pioneered the research and development of fast growing clonal eucalyptus strains, and has developed varieties which are particularly well suited for the sandy soils of the Kouilou area of the Republic of Congo. The trees typically reach 22 to 26 meters (70 to 85 feet) in seven years, at which point they are harvested and the area is then replanted. Although past operations were based on the export of logs, the new business plan will expand into value added products such wood chips, utility poles, lumber and wood-pellets (bio-fuel) for which significant international off-takers and operators have confirmed their intention to participate.

EFC currently ships up to 20,000 tonnes of pulp logs per month to Europe for annualized revenues of approximately US$12 million. The Company has received expressions of interest for volumes up to 1 million tonnes annually partially due to the high quality provided by the eucalyptus fibre. EFC is now one of the largest employers of local residents in the Republic of Congo.

MagForestry’s recent independent technical audit by R. B. Cormier Inc. (“RBC”) advised that the EFC operation, at full optimization, could represent one of the worlds lowest cost sources of wood fibre suited to high yield hardwood pulp. RBC specifically noted that EFC has the unusual competitive advantage of eventually being able to harvest up to 1.6 million tonnes annually, all with in a 50 km radius of Pointe-Noire, West Africa’s best deep-water port. RBC also confirmed that due to the existing mature forest inventory 1.2 million tonnes is currently available annually for log sales and wood chips.

MagForestry has recently completed a feasibility study for a log chipping mill. The results were sufficiently robust for the Company to retain the services of SIVEST, a South African based contractor, to begin the construction of a 500,000 tonne per year log chipping plant. The plant, to be located dockside on land in the Port of Pointe-Noire controlled by EFC, is expected to be operational by the end of 2007.

About MagIndustries Corp.:

MagIndustries’ resource subsidiaries are operating and developing major industrial projects in the Republic of Congo (ROC) and the Democratic Republic of Congo (DRC).

- MagEnergy, a wholly owned subsidiary, is the leading participant in the refurbishment (Phase I) and rehabilitation (Phase II) of the 1424MW INGA II hydro-electric station on the Congo River in the DRC. Industrial Development Corp. of South Africa holds a 30% interest in Phase I and a 15% interest in Phase II. – MagForestry, a division of MagIndustries, controls 100% of Eucalyptus Fibre Congo, an operating 68,000 hectare eucalyptus plantation which overlies MagIndustries’ Makola Mineral License near Pointe-Noire, ROC. – MagMinerals, a wholly owned subsidiary, is developing of a 600,000 tpy potash (fertilizer) plant near Pointe-Noire, ROC. – MagMetals, a wholly owned subsidiary, is planning the development of a 72,000 tpy magnesium smelter adjacent to MagMinerals’ potash plant for the production of magnesium alloys for the global automotive industry. The raw materials for the MagMinerals and MagMetals plants will be sourced by solution mining MagIndustries’ 100% owned carnallite (magnesium and potash salt) deposits which underlie the Makola Mineral License near Pointe-Noire. – MagMining, currently a wholly owned subsidiary, will be responsible for the operation of the solution mine operation and the delivery of the raw material brine to MagMinerals and MagMetals. The government of the Republic of Congo may eventually hold a 10% interest.

MagIndustries Corp. is a Canadian company whose common shares are listed on the TSX Venture Exchange and trades in Canadian currency under the symbol “MAA”. The Company has 152,597,526 shares outstanding on an undiluted basis. More information on the Company is available at its website, www.magindustries.com.

Except for historical information, this press release contains forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, and other risks detailed from time-to-time in the Company’s ongoing filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events in this press release might not occur.

Cusip: 55917T 102

Contact:
William (Bill) Burton
MagIndustries Corp.
President & CEO
(416) 368-7911
wburton@magindustries.com

Stephane Rigny
MagIndustries Corp.
Executive V P Finance
+27-11-263-7702
srigny@magindustries.com

GWR Resources (GWQ – TSX Venture) is pleased to announce the results of the first 2006 drill hole from the Aurizon Zone at the Lac La Hache property, BC.
DDH AZ-06-01, drilled at 60 degrees, azimuth 300 degrees, has intersected significant mineralization over 303.89 metres true length. The hole was suspended when the capacity of the drill rig was reached, but still in the sulphide-bearing lithology. AZ-06-01 was drilled to test at depth, native copper mineralization on surface, which was uncovered by surface trenching. Four additional north-south trenches, located to the west of the collar, spaced approximately 50 metres apart, all exhibit similar mineralization at surface. The zone is open on three sides, and at depth.
     Assay result highlights are shown in the following table.
        From      To     Length (m)  Au (g/t)   Cu (%)
     ————————————————–
       35.29    115.73     80.437      .563      .285
       140.01   148.66      8.651      .942      .277
       161.75   208.53     46.782      .385      .194
       229.48   272.19     42.705      .403      .227
       272.19   292.32     20.135      .821      .476
     ————————————————–
Average grades from 35.29 metres to 292.32 metres (257.032 metres) are 0.439 Au(g/t), and 0.223 Cu (%).
DDH AZ-06-01 is the first hole drilled in the 2006-2007 program, wherein the main focus is to evaluate anomalies in an airborne gamma-ray spectrometric survey conducted by the Geological Survey of Canada, in partnership with GWR Resources. (See news release of October 11, 2005)

DDH AZ-06-02 will be collared 20 metres south and 60 metres west of DDH AZ-06-01, and drilled at 70 degrees azimuth 300 degrees, positioned to evaluate further the surface expression of native copper mineralization in the zone. Based upon these two holes, DDH AZ-06-03 will be positioned and drilled at 90 degrees to test the vertical extent of the mineralization.

This first 2006 drill hole was funded in part by the MineralFields Group through a private placement. Additional drilling will largely be funded by the MineralFields Group through the $3,000,000 private placement which closed on September 20, 2006.

The Company has entered into a written agreement with Connors Drilling Ltd. of Kamloops B.C. to provide drilling services commencing October 11, 2006.

The Company is pleased to announce that Kevin Bay has agreed to join the Board of Directors.
“Irvin Eisler”
—————–
Irvin Eisler, President
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
    
For further information
GWR RESOURCES INC.: 5230 Lansdowne Road, Armstrong, British Columbia, V0E 1B4, Telephone: (250) 546-8048
Source: GWR Resources Inc.

AXMIN Inc. (TSX VENTURE:AXM – News) is pleased to report an initial inferred mineral resource estimate of 4.9 million tonnes assaying 2.5 g/t Au (392,000 contained ounces of gold) on the Komahun Prospect at the Nimini Hills project in Sierra Leone. This resource estimate was completed by independent consultant SRK Consulting (UK) Ltd. (“SRK”) and is based on the drill holes located in the central portion of the shear zone (see releases dated July 18, January 24, 2006 and November 17, 2005). The resource does not take into account the known and previously reported parallel structures which are the subject of a current drill program.
 
Chief Executive Officer Jonathan Forster stated “Komahun resource represents an excellent start to a program on a grassroots project where we only started drilling twelve months ago. We believe there is great potential for resource expansion not only from the parallel structures already identified but from other targets along strike that are currently emerging. With Passendro in the Central African Republic in feasibility study, resources at Kofi Project in Mali anticipated to continue to expand, and now resource success at Komahun in Sierra Leone, we believe we have strong foundations for future growth.”

AXMIN has just taken delivery of its own man portable core rig for Sierra Leone which has immediately commenced drilling on the two high grade veins on the Eastern Structure where previous drilling intersected 47.5 g/t Au over 3 metres and 66 g/t Au over 2 metres in separate veins. Recent trenching has traced similar looking quartz vein material along a minimum strike length of 250 metres from these intersections open at both ends. Trenching has also extended the geochemical anomaly overlying the Western Structure where a single previous reconnaissance drill hole intersected 4.2 g/t Au over 3.9 metres.

Recent grid sampling has confirmed a 2,000 metre geochemical anomaly (greater than 50 ppb threshold) sampled on grid lines mainly 200 metres apart on the southern extension of the Komahun prospect with spot values of up to 600 ppb. This anomaly lies over an area with similar structures, rock types and aeromagnetic signature to Komahun. Trenching is currently underway on this anomaly with drilling to follow when a rig is available.

The inferred mineral resource estimate has been based on some 3,200 metres of core drilling and has been compiled in accordance with National Instrument 43-101 by independent consultants SRK under the supervision of Dr Michael Armitage (CGeol, CEng, MIMMM). SRK’s report will shortly be available on the SEDAR website. The inferred resource estimate was established using ordinary Kriging on data with a top cut of 25 g/t Au and using a 0.5 g/t Au cut off from drilling on mainly 80 metre fence spacing.
Komahun Inferred Mineral Resource                             Tonnes         Grade      Contained

Gold                                 Kt                g/t Au          (0z)
Oxide                               500              2.5             41,000
Sulphide                           4,370           2.5             352,000
Total                                4,870           2.5             392,000 Figures have been rounded to the nearest thousand

AXMIN, the project manager, may earn a 60% interest in the Nimini Hills project from a subsidiary of Eldorado Gold Corporation (TSX:ELD – News; ASX:EGO – News) by expenditure of US$2.25 million over a three year period, and fulfilled its minimum expenditure payment of US$0.5 million in the first year. Thereafter Eldorado has the right to participate on a pro rata basis or if it elects not to then AXMIN can earn an additional 20% by producing a Bankable Feasibility Study. The monies spent on Eldorado’s behalf to earn this additional 20% will be recovered by AXMIN from Eldorado’s share of future production.

Core samples have been prepared and 50 gram pulps subject to gold analysis by fire assay at the independent SGS Laboratory facility at Siguiri in the Republic of Guinee. This press release has been reviewed by in-house qualified person Dr. Jonathan Forster, Fellow of the Institute of Materials, Minerals and Mining in the United Kingdom.

AXMIN is a mineral exploration company with a strong focus on gold in highly prospective properties across central and west Africa. For more information regarding AXMIN visit our website at www.axmininc.com.

Certain statements contained herein, as well as oral statements that may be made by the company or by officers, directors or employees of the company acting on the company’s behalf, that are not statements of historical fact, may constitute “forward-looking statements” and are made pursuant to applicable and relevant national legislation (including the Safe-Harbour provisions of the United States Private Securities Litigation Reform Act of 1995) in countries where AXMIN is conducting business and/or investor relations. Forward-looking statements, include, but are not limited to those with respect to the price of gold, the estimation of mineral reserves and resources, the realization of mineral reserves estimates, the timing and amount of estimated future success of exploration activities, AXMIN’s hedging practices, currency fluctuations, requirements for additional capital, government regulation of mining operations, environmental risk, title disputes or claims limitations on insurance coverage and the timing and possible outcome of pending litigation. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “does not expect”, “is expected”, “budget”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or equivalents or variation, including negative variation, of such words and phrases, or state that certain actions, events or results, “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the actual results of current exploration activities, conclusions of economic evaluations, changes in project parameters as plans continue to be refined, possible variations in grade and ore densities or recovery rates, failure of plant, equipment or processes to operate as anticipated, accidents, labour disputes and other risks of the mining industry, delays in obtaining government approvals or financing or in completion of development or construction activities. Although AXMIN has attempted to identify important factors that could cause actual actions, events or cause actions events or results not to be anticipated, estimated or intended, there can be no assurance that forward looking statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Except as may be required by applicable law or stock exchange regulation, the company undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events. Accordingly, readers should not place undue reliance on forward-looking statements.

For a Drill Hole – Trench Map, please click on the link below:

http://www.ccnmatthews.com/docs/axm1005.pdf

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.
Contact:
Jon Forster
AXMIN Inc.
Chief Executive Officer
+44 (0)1233 665600 (UK)
+44 (0)1233 643728 (UK) (FAX)

Judith Webster
AXMIN Inc.
Manager – Investor Relations
(416) 368-0993 (Canada)
Email: ir@axmininc.com
Website: www.axmininc.com

Hy-Drive Technologies Ltd. (TSX-V: HGS) announced today that TransFuel Limited will become the exclusive master sales agent for Hy-Drive® Hydrogen Generating Systems (HGS) throughout the United Kingdom.  To initiate the agreement and to begin immediate sales in the UK, TransFuel has ordered $300,386 of HGS inventory.

Paul O’Neill, Managing Director of TransFuel is excited at the prospects of the UK marketplace. “Having been involved in the UK heavy goods vehicle market for six years we are delighted to be working with Hy-Drive.  We have evaluated many after market products that claim to improve engine efficiency and reduce emissions, and the Hy-Drive HGS delivers by far the best, most practical solution for the commercial vehicle operator.  The UK and wider European Union lead the world in terms of emissions regulations and there is a large and growing demand for solutions that meet these requirements.”

TransFuel has an existing, established network of agents across the United Kingdom which will initially focus their sales efforts on the over 500,000 Heavy Goods vehicles operating in the region, considerably increasing the size of Hy-Drive’s immediately accessible market.

“We are excited to align with TransFuel to introduce the technology in the very large UK market,” said Tom Brown, President of Hy-Drive.  “We have set high but achievable performance targets with TransFuel that, if reached, will have a significant positive impact on our financial results.”

This agreement is part of Hy-Drive’s controlled and planned roll out of distribution agreements with third party partners across the globe.  This agreement adds to a number of others including IntraLink and Mining Technologies International in North America, and Sparta & Associates in the Asia-Pacific region.  Agreements to distribute Hy-Drive’s Clean Burn Technology(TM) into the European Union, South America and other markets are proceeding as per Hy-Drive’s strategic growth plan.

About Hy-Drive
Hy-Drive is an energy technology firm that has developed a proprietary, patented hydrogen generating system. The Hy-Drive system generates and injects hydrogen gas into a regular internal combustion engine, enhancing the combustion process by allowing fuel to burn more efficiently and completely. In previous extensive customer trials and third party tests, the Hy-Drive system has demonstrated significant performance enhancements, including reduced emissions, increased torque/horsepower and significant fuel savings. These benefits, specifically fuel economy and reduced emissions, provide customers with greater productivity overall, as their engines operate more efficiently, with improved cycle times and less carbon build-up. For further information, visit www.hy-drive.com.

About TransFuel
TransFuel Ltd. is a UK based alternative energy firm specializing in dual-fuel solutions for UK’s heaviest fuel users.  Based out of Southampton, TransFuel has extensive experience in the use of liquefied petroleum gas in dual fuel applications.  TransFuel has an existing established network of agents across the United Kingdom who have worked with heavy goods vehicles, various marine vehicles and also in stationary diesel applications.

Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this press release may constitute forward-looking statements. Such statements reflect Hy-Drive’s current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause Hy-Drive’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including among other things, those which are discussed under the headings “Risk Factors” and elsewhere in documents that Hy-Drive files from time to time with securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Hy-Drive does not intend, and does not assume any obligation, to update these forward-looking statements.

For more information, please contact:

Investor Relations:
Glen Akselrod
Bristol Capital Ltd.
Tel: (905) 326-1888
glen@bristolir.com

OR

Tom Brown, President
Hy-Drive Technologies Ltd
Tel: (905) 542-3024, ext. 300
tombrown@hy-drive.com

Mr. Carol Murray, president and chief executive officer of Power Tech Corporation Inc., “PowerTech” or the “Company” (TSX-V: PWB), is pleased to announce the signing of two new distribution agreements with the companies Toromont Industries Ltd. and Thiessen Equipment Ltd., two renowned players in their respective business sectors.

The agreement concluded with Toromont, a major dealer of Caterpillar heavy equipment, will enable PowerTech to market its products in the provinces of Ontario, Manitoba and Newfoundland. For its part, Thiessen is a world-renowned mining equipment specialist that distributes its products notably in Canada and the United States. By adding PowerTech’s PicBucket to its product catalogue, Thiessen can offer its clientele a new and innovative solution for highly specialized mining sector applications. The PicBucket is a multifunctional percussion bucket that allows for great efficiency improvements for a variety of work, such as excavation and demolition.

“Toromont is a powerful ally for PowerTech. Solidly established in English Canada, particularly in Ontario, Toromont will give us access to a vast network of construction entrepreneurs via its extensive network of branches. Meanwhile, the agreement with Thiessen will allow us to develop a major niche market throughout Canada and the United States. With these two agreements, PowerTech has reached an important milestone in its commercialization plan,” stated Mr. Murray.

The PicBucket: Conclusive tests by distributors
“PowerTech is a dynamic team that possesses high-level expertise and marketing know-how in addition to an innovative technology. We believe that the technology developed by PowerTech meets a pressing need in various market segments, such as: excavation entrepreneurs, municipalities and companies specialized in public utilities projects. Following on-site trials of the PicBucket, we anticipate a very positive reaction from our clients to this equipment, which has no equivalent on the market,” said Mr. Bob Mennie, Allied Product Manager at Toromont.

“The first time that I saw the PicBucket in action, I immediately understood the potential of this innovative percussion bucket for our mining industry clients. We are convinced that our clients will come to the same conclusion and will want to quickly benefit from the advantages offered by the PicBucket’s efficiency and exceptional performance,” said Mr. Scott Trainor, General Manager of Thiessen Equipment.

In addition to these new alliances with Toromont and Thiessen, PowerTech has also signed distribution agreements with the company Finning Canada, a major Caterpillar equipment dealer in Western Canada, as well as with sister companies Low Country Machinery and Central Georgia JCB, which operate in the State of Georgia in the United States. “With the support of these first-rate partners, PowerTech intends to expand its presence in several promising markets in Canada and the United States. In addition, we are backed by an internal business development team made up of three seasoned regional managers who cover the entire Canadian market. Today, we can affirm that PowerTech has brought together all the necessary ingredients to enable the Company to achieve accelerated growth in the coming months,” said Mr. Yves Sicotte, Vice President, Sales and Marketing.

About Toromont
Toromont Industries Ltd. is one of the world’s largest Caterpillar dealerships by revenue and geographic territory in addition to industry leading rental operations. Toromont employs approximately 4,400 people in more than 115 locations.

Toromont represents Caterpillar and other equipment lines, maintaining dealerships in Manitoba, Nunavut, Ontario, Newfoundland and Eastern Labrador, and through Battlefield Equipment Rentals is one of Canada’s premier construction equipment rental companies.

About Thiessen
Thiessen Team, a company based in Langley, British-Columbia, provides mining equipment, mining tools, mining machinery and mining supplies to the resource industry. We are an international company with offices in Canada, the USA, Africa, South America and Australia. Thiessen Team is a solutions driven manufacturer and supplier, dedicated to providing cost-effective products and services to the global mining community and related industries.

About PowerTech (www.powertechci.com)
PowerTech is the only company in the world that manufactures and commercializes a percussion bucket for the construction, demolition, aluminum, mining, tunnel digging, forestry and military industries. PowerTech’s PicBucket is a technological breakthrough that combines the power of a hydraulic hammer with the stripping force and maneuverability of a conventional bucket.

PowerTech intends to position itself as a leader in the development, integration and commercialization of leading edge technologies that allow for substantial improvements in equipment performance, productivity and functionality.

(*) The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

For further information:
Carol Murray, President and Chief Executive
Officer, Power Tech Corporation Inc.
carol.murray@powertechci.com, (450)963-6400;
Yves Sicotte, Vice-president Sales and Marketing,

Power Tech Corporation Inc.,
yves.sicotte@powertechci.com, (450) 963-6400;
Frédéric Tremblay, HKDP, (514) 395-0375, ext. 234
ftremblay@hkdp.qc.com;

Source:
PowerTech Inc. Corporation, www.powertechci.com

CanWel Building Materials Income Fund (the “Fund”) today announced that its majority owned subsidiary CanWel Holding Partnership LP (“CanWel LP”, together with its subsidiary entities, “CanWel”) has entered into a letter agreement (the “Purchase Agreement”) with Western Pacific Wood Preservers Ltd., Western Cleanwood Preservers Ltd., Alberta Wood Preservers Ltd., Eastern Wood Preservers Ltd. and Quebec Wood Preservers Ltd., (collectively, the “Vendors”) in connection with the acquisition (the “Acquisition”) of the assets of five lumber pressure treating plants (the “Plants”). The five plants are located at or near Surrey, BC (2), Edmonton, AB, Toronto ON, and Montreal QC, and have been suppliers to the Fund for many years. CanWel’s assets following the Acquisition will include the five Plants and 17 distribution centres strategically located across Canada.

The purchase price for the Plants will be satisfied as follows: the issuance to the Vendors of 3,111,111 exchangeable class B CanWel LP units, the payment to the Vendors of approximately $21 million in cash, and pursuant to a vendor take back loan, the net issuance to the Vendors of promissory notes in the aggregate maximum principal amount of $3.8 million. CanWel LP intends to fund the cash component of the purchase price from existing credit facilities of the CanWel group. The promissory notes will be repayable in equal monthly installments over a period of 3 years.

Tom Donaldson, President and CEO of the Fund said, “We have examined many strategies to build vertical integration capabilities where it makes operational and economic sense to CanWel. The Acquisition provides us with an integrated capability in treated lumber that is expected to enhance our profitability and growth strategies, as CanWel is currently the largest customer of the Plants. By vertically integrating these operations, CanWel reinforces its position within the pressure treated arena. This transaction is not only a strategic move, but the addition of the Plants within CanWel is also expected to be accretive and to generate EBITDA available to the Fund of approximately $ 6.8 million annually.”

The Acquisition will be a related party transaction for purposes of OSC Rule 61-501. The Chairman of the Fund, Amar Doman, and a holder, directly or indirectly, of approximately 33% of the Fund’s units, is also the direct or indirect owner of the Vendors. As a result of Mr.Doman’s financial interest in the transaction, he has abstained from voting on this transaction and the Trustees of the Fund have set up a special committee of independent trustees to review the transaction, manage the Acquisition and provide recommendations to the full Board of Trustees. The Special Committee has retained independent financial and legal advisors, including GMP Securities L.P. to assist it with this mandate.

The more detailed considerations and recommendations of the Special Committee will be provided to unitholders in an information circular to be sent to unitholders in connection with a special meeting of unitholders, notice of which has previously been provided, and which is to be held on or about November 14, 2006 (the “Meeting”). The record date for the meeting is September 15, 2006. At the Meeting, the Fund will seek approval by a majority vote of the disinterested unitholders of the Fund attending the Meeting in person or by proxy, in accordance with the requirements of applicable Canadian securities laws.

The transaction is expected to close in January 2007 and is subject to the Fund’s continuing due diligence and the entering into of definitive documentation containing customary terms and conditions, including the approval of the Trustees of the Fund, approval of the Fund’s unitholders as described above, and receipt of all necessary regulatory approvals and third party consents.

About CanWel.
The Fund trades on the Toronto Stock Exchange under the symbol CWX.UN and is one of Canada’s largest national distributors in the building materials and related products sector, operating 17 distribution centres across Canada. The Fund distributes a wide range of hardware, building materials, lumber and renovation products.

Further information on the Fund can be found in the disclosure documents filed by CanWel Building Materials Income Fund with the securities regulatory authorities, available at www.sedar.com.

For further information regarding CanWel please contact:

Tom Donaldson
President and CEO
604 432 1400

Ali Mahdavi
Investor Relations
416-962-3300 or +1(866) 430-6247
amahdavi@genoa.ca

Mr. David Little reports

AVERY RESOURCES PREPARES FOR AUSTRALIAN PRODUCTION STARTUP AND PROVIDES EXPLORATION UPDATE

Avery Resources Inc.’s operator at its Toparoa-1 oil discovery has begun production start-up operations in the South Australian sector of the Cooper basin. Avery has a 32.67-per-cent interest in the well. An arrangement was made to produce the Toparoa-1 oil into the recently built-out pipeline system, rather than trucking the oil, and Avery has received a $1.4-million cash payment as compensation for the necessary timeline revision. With regard to exploration activity, Avery is planning a three-well back-to-back drilling program in December, 2006, in the Queensland sector of the Cooper basin, and an additional seven wells are planned in the Cooper basin throughout 2007 and into the first quarter of 2008.

“Avery is looking forward to a busy and exciting fourth quarter in Australia,” said David Little, chairman and chief executive officer of Avery Resources. “With our first Australian production coming on stream and a busy seismic and drilling program planned, we are working hard to add value for our shareholders.”

Production
Production from Toparoa-1, located in the Murteree block of PEL 113 (Avery 35 per cent) in the South Australian sector of the Cooper basin, is expected imminently, subject to crew scheduling by the field operator, Santos Ltd. In recognition of the Toparoa-1 production delays and in accordance with the production arrangement, Avery negotiated and received a payment of $1.4-million. Production via pipeline will eliminate the increased risk of downtime associated with trucking, including adverse weather and difficult roads, in this outback location.

Toparoa-1 drill stem tested at 1,814 barrels of oil per day (bopd). The well will initially free flow into an on-site storage tank, prior to diverting to the flow line. An ESP (electric submersible pump) is planned to increase production by late October. It will produce from the Hutton sandstone formation similar to the adjacent Derrilyn oil field, 1.3 kilometres to the northeast, which is also operated by Santos. With approximately the same net pay interval, Derrilyn-1 produced approximately 500,000 barrels of oil from the formation in its first 12 months of production.

Exploration
Avery is planning substantial fourth quarter 2006 seismic and drilling activity in the Barta and Wompi licence blocks located in the Queensland sector of the Cooper basin. Avery has the right to earn up to 50 per cent in the Barta/Wompi project.

Avery and its partners have reserved a rig to embark on a three-well back-to-back program in the ATP 752P Wompi block (236,700 acres). Drilling of the wells is expected to begin in December. The three wells will be Maracoonda-2, Nora-1 and Gamma-1. With potential for an extended accumulation up dip, Maracoonda-2 will test an interpreted three metres of net oil pay in the Hutton sandstone first detected in Maracoonda-1. Nora-1 will test a robust structure that is along trend with the Watson and Watson South oil fields. These fields are located in the adjoining production licence and they have produced more than three million barrels of oil to date. Gamma-1 will test a structure that is located up dip from two wells that had strong oil shows in multiple horizons (Rho-1 and Rho East-1).

Avery has seismic programs planned in the ATP 752P Barta block (631,100 acres), beginning in October, 2006. A 3-D seismic survey is being conducted over the Cook oil field adjacent to the licence boundary, and Avery and its joint venture partners will acquire an extension into the Barta block, aimed at detailing two potential field extension structures. On completion of the 3-D survey, the joint venture will acquire a 100-kilometre 2-D infill survey over the Vancouver and Bligh series of structures. The 3-D and 2-D surveys will be used to determine drilling locations planned for the second quarter of 2007.

Also, beginning in October, 2006, Avery will participate in a 3-D seismic survey in block AC/P24 of the Timor Sea offshore Australia, to determine an appraisal well location for the Katandra-1 oil discovery. Avery has a 10-per-cent interest in Katandra.

OutdoorPartner Media Corporation (“OutdoorPartner” or the “Company”) (TSXV: OPX) is pleased to announce that the Company’s payphone kiosk advertising division, Intelligent Media Corporation d.b.a. Prime Point Media (“Prime Point”), has signed contracts with national advertisers valued in excess of US$860,000 since the acquisition of Prime Point by the Company on August 17, 2006.

Prime Point has also signed a contract for its first PrimeCasting campaign. PrimeCasting enables advertisers to deliver branded, multimedia content to consumers’ mobile phones and PDAs via Bluetooth transmitters located in payphone kiosks. “Bluetooth marketing campaigns are becoming commonplace in Europe and are starting to gain traction in North America”, stated OutdoorPartner’s CEO, Mark Brodkin. “Prime Point has a network of over 700,000 potential Bluetooth broadcasting sites, which are ideal for Bluetooth campaigns because they are located in close proximity to consumer traffic. Due to the size and location of Prime Point’s payphone network, PrimeCasting represents a significant growth opportunity as advertisers continue to recognize Bluetooth’s power to engage consumers”, added Brodkin.

In addition, OutdoorPartner has contracted over 90% of its PartnerBin inventory in New York City. “The response to PartnerBins in New York has been overwhelmingly positive. OutdoorPartner’s success in New York combined with Prime Point’s recent wins serve as confirmation of our strategy to marry OutdoorPartner’s local sales competency with Prime Point’s national sales competency”, said Brodkin.

About OutdoorPartner:
OutdoorPartner operates in the fast-growing alternative media segment of the out-of-home advertising industry in the 50 top U.S. designated market areas. OutdoorPartner is a market leader providing alternative out-of-home media solutions for advertisers on an inventory of over 700,000 payphone kiosks and PartnerBin advertising receptacle displays.

This document may contain forward-looking statements, relating to OutdoorPartner’s operations or to the environment in which it operates, which are based on OutdoorPartner’s operations, estimates, forecasts and projections. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and/or are beyond OutdoorPartner’s control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. Factors that may cause such differences include, but are not limited to, OutdoorPartner’s lack of operating profits, its dependence on key personnel, general economic conditions and other external events that may impact on customers’ advertising spending, competition from other out-of-home advertisers and other media and government regulation seeking to limit or restrict OutdoorPartner’s activities. More detailed information about these and other factors is included in Outdoor Partner’s 2005 Annual Information Form and other filings with the Canadian securities regulatory authorities. Consequently, readers should not place any undue reliance on such forward-looking statements. OutdoorPartner disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information:
Mark Brodkin, CEO, OutdoorPartner Media Corporation
296 Richmond Street West
Suite 305, Toronto, Ontario
M5V 1X2, Canada

T: (416) 602-1602
F: (416) 352-5070
www.outdoorpartner.com

Elan Corporation, plc (“Elan”) (NYSE:ELN – News) and Transition Therapeutics Inc. (“Transition”) (TSX: TTH – News), today announced an exclusive, worldwide collaboration agreement for the joint development and commercialization of a novel therapeutic agent, AZD-103, for the treatment of Alzheimer’s disease. AZD-103 is a small molecule compound in Phase I clinical development that acts by breaking down and preventing the assembly of beta amlyoid fibrils, a hallmark pathology of Alzheimer’s disease.

Under the terms of the agreement, Transition will receive upfront payments of US$15 million: US$7.5 million in 2006 and the remaining US$7.5 million in 2007. In addition, dependant upon the successful development, regulatory approval and commercialization of AZD-103, Transition will be eligible to receive milestone payments of up to US$185 million. Elan and Transition will share the costs and operating profits of AZD-103 if successfully developed and commercialized. Each party’s cost share and ownership interest may vary throughout the term of the Agreement dependant on certain elections that may be made during the development of AZD-103.

“We are delighted to have this opportunity to work closely with Dr. Cruz and his team at Transition. The opportunity to advance this program to provide much needed therapeutic choice in the treatment of Alzheimer’s will be a strategic priority and focus for all of us here at Elan. By joining forces, we increase our probability of success. The AZD-103 program represents a significant addition to our scientific portfolio and continues to reinforce our commitment and leadership in bringing more therapeutic choice to patients and their caregivers suffering from Alzheimer’s around the world,” said Kelly Martin, Chief Executive Officer and President of Elan.

“We are extremely pleased to have Elan as our collaborator in developing AZD-103. Elan shares our vision and commitment to develop an effective Alzheimer’s disease therapy. We are confident this collaboration will allow us to fully achieve the potential of the disease-modifying compound AZD-103 and help make a difference in the lives of millions of Alzheimer’s disease patients and their loved ones,” said Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition.

Conference Call
Transition will hold a conference call at 11:00am Eastern time on Wednesday, September 27th, 2006 to discuss today’s news in more detail. This call is open to the public and can be accessed live either over the Internet from the company’s website www.transitiontherapeutics.com or by dialling 1 (888) 633-8341 or (416) 620-5690.

About the AZD-103 Drug
AZD-103 is a novel therapeutic agent in Phase 1 clinical development for the treatment of Alzheimer’s disease that has the potential to both reduce disease progression and improve symptoms such as cognitive function. As reported recently in a Nature Medicine publication, oral treatment with AZD-103 reduced accumulation of amyloid beta and amyloid beta plaques in the brain, and reduced or eliminated learning deficits in a leading transgenic mouse model of Alzheimer’s disease. In addition, AZD-103 is well positioned as a potential Alzheimer’s therapy as it is a small molecule, crosses the blood brain barrier and has exhibited a favorable safety profile.

About Alzheimer’s disease
Alzheimer’s disease is a progressive brain disorder that gradually destroys a person’s memory and ability to learn, reason, make judgments, communicate and carry out daily activities. The disease affects more than 4 million Americans and approximately 20 million people worldwide, and with an aging population incidence of Alzheimer’s disease is expected to double over the next 20 years. Currently approved Alzheimer’s therapies treat some disease symptoms but do not reverse or slow down disease progression. These products have worldwide annual sales of US$3.1 billion; however, the Alzheimer’s pharmaceutical market is expected to grow significantly with the arrival of products that have the potential to alter disease progression.

About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit www.elan.com.

About Transition
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition’s lead products include regenerative therapies E1-I.N.T.(TM) and GLP1-I.N.T.(TM) for the treatment of diabetes, AZD-103 for the treatment of Alzheimer’s disease, and HCV-I.E.T. for the treatment of hepatitis C. Transition has a strong pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. Transition’s shares are listed on the Toronto Stock Exchange under the symbol “TTH”. For additional information about the company, please visit www.transitiontherapeutics.com.

Forward Looking Statement
This press release contains forward-looking statements regarding the collaboration agreement between Elan and Transition. These statements are based on Elan’s and Transition’s current beliefs and expectations. AZD-103 may not be successfully developed or commercialized under the collaboration agreement. Factors which could cause actual results to differ materially from Elan’s and Transition’s current expectations include the risks that clinical development of AZD-103 fails due to safety or efficacy issues, the results from preclinical testing of AZD-103 are not predictive of results obtained in clinical trials, that any patents will issue with respect to AZD-103 or that, even if issued, whether such patents would provide substantial protection or commercial benefit, the development and commercialization of competitive therapies, the collaboration agreement is terminated early or Elan and Transition encounter other unexpected delays or hurdles. Drug development and commercialization involves a high degree of risk. For more detailed information on the risks and uncertainties associated with Elan’s drug development and other activities, see the periodic and current reports that Elan has filed with the Securities and Exchange Commission. For more detailed information on the risks and uncertainties associated with Transition’s drug development and other activities, see the risk factors and other cautionary statements discussed in Transition’s quarterly and annual filings with the Canadian commissions. Elan and Transition assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information
Elan Contacts: Investor Relations: Emer Reynolds, Chris Burns,
Ph: 353-1-709-4000, 1-800-252-3526
Media Relations: Davia Temin, Ph: (212) 407-5740
Elizabeth Headon, Ph: 353-1-498-0300

Transition Therapeutics Contacts: Dr. Tony Cruz, Chief Executive Officer,
Ph: (416) 260-7770, x.223
Mr. Elie Farah, CFO and VP, Corporate Development, Ph: (416) 260-7770, x.203

Mr. Andrew Carter, President, is pleased to provide an update of exploration completed at Tinka Resources Limited’s 100% owned 2,079 hectare Colquipucro project in west-central Peru. The Colquipucro mining district is located 190km NE of Lima, within the richly mineralized Zinc-Lead-Silver Belt of Central Peru. The project lies 25km northwest of the famed Cerro de Pasco and Colquijirca Pb-Zn-Cu mines, 35km east of the Raura Cu-Pb-Zn-Ag mine, and 25km southwest Buenaventura´s 150 million ounce Uchuccahacua Ag mine.

The Company’s field geologists have identified 3 distinct zones of interest on the project. Dr. Andre Panteleyev (Ph.D., P.Eng.), a consulting geologist to Tinka, recently visited the project to assess these zones and make recommendations, in consultation with the Company’s Qualified Person John Nebocat (P.Eng.), for a comprehensive sampling program.

In Zone 1, centrally located within the project, a series of narrow, widely-spaced quartz veins trending roughly east-west, crosscut a sandstone formation which strikes more or less north-south and dips gently to the west. The veins can be traced over a distance of at least 400m. In recent months, access to the main underground workings have been restored, existing trenches cleaned out and new trenches excavated in the three areas of the property. An extensive program of rock chip channel sampling and geological mapping is now complete from both trenches and underground exposures, with a total of 68 underground and 125 surface samples taken.

Results are available for 45 samples, taken from the 230m long principal adit in the centre of the project area. Highly anomalous Ag, Pb and Zn has been discovered along the length of these working, with mineralization developed both in discrete veins and within the sandstone and host rock. Any veins present were sampled separately across their widths, yielding values from 1.7 g/t Ag to 657 g/t Ag (21 oz/t) over widths ranging from 0.1m to 1.0m.

Wallrock to these veins was sampled as channels across bedding from the back (roof) to the base of one wall of the adit at 5m intervals along the adit’s length. These samples ranged from 3 g/t Ag to 300 g/t Ag over widths ranging from 2.5m to 3.0m, confirming the presence of significant mineralization away from the visible vein-style mineralization. A strongly mineralized zone was encountered between 60m and 95m from the adit portal, where seven consecutive wallrock samples of 3.0m width averaged 100 g/t Ag (3.2 oz/t) over this 35m interval. Two adjacent channel samples taken across a fractured and brecciated fault to the north of this zone yielded 688 g/t Ag over 1.0m and 613 g/t Ag over 3.0 m.

Mr Carter comments “We are very pleased to have discovered this significant wallrock zone of silver mineralization in addition to the high grade vein material that was the target of the previous mining operation. The 35m wide zone of highly elevated silver is now being sampled along its entire length to check the continuity of mineralization. As no vein material was included in the samples, these initial results support the strong potential for a bulk-mineable silver deposit within this extensive historic mining district.”

In addition to check sampling the area of interest in the underground workings, a program of surface channel sampling will commence shortly to test Zone 1 along its entire 400m length. Five trench lines, spaced 100m apart and each 275m to 300m long, will test this zone.

The Company’s Qualified Person, John Nebocat (P.Eng.), has reviewed and approved the contents of this press release.

On behalf of the Board,
“Andrew Carter”
Andrew Carter, President & CEO

Forward Looking Statements.
This Company news release contains certain “forward-looking” statements and information relating to the Company that are based on the beliefs of the Company’s management as well as assumptions made by and information currently available to the Company’s management. Such statements reflect the current risks, uncertainties and assumptions related to certain factors including, without limitations, competitive factors, general economic conditions, customer relations, relationships with vendors and strategic partners, the interest rate environment, governmental regulation and supervision, seasonality, technological change, changes in industry practices, and one-time events. Should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein. Neither the TSX Venture Exchange nor the Frankfurt Deutsche Börse have reviewed the information contained herein, and, therefore, do not accept responsibility for the adequacy or accuracy of this release.

For further information
Investor information contact: Nick L. Nicolaas at (604) 657-4058, or email: nicolaas@attglobal.net, website: www.tinkaresources.com

Mr. Michael Magnus reports

SHEAR WIND AND VINDT RESOURCES INC. ANNOUNCE JOINT VENTURE AGREEMENT IN ALBERTA WIND FARM PROJECT

Shear Wind Inc. and Vindt Resources Inc. have established a joint venture to develop the Coyote Ridge Wind Park project, outside Lethbridge, Alta., an area of 13,500 acres.

An initial project resource assessment prepared by Phoenix Engineering indicates a long-term predicted energy yield of approximately 700 gigawatts per hour per year, designed around a wind park consisting of 100-to-200-megawatt wind turbines. This corresponds approximately to a plus-40-per-cent capacity factor as determined by the wind data measurements collected from two 60-metre MET towers over a 12-month period.

Mike Magnus, president of Shear Wind, states: “We are extremely pleased with the results of this 12-month property assessment and the potential energy to be harnessed in a wind park of such magnitude. Furthermore, we are particularly excited about having Vindt as a joint venture partner in the development of Coyote Ridge Wind Park.”

Shear Wind has already established itself as a provider of wind-generated energy in Atlantic Canada. The Coyote Ridge venture represents a key strategic step in the realization of the company’s planned expansion into other markets in Canada and the United States.

Wind is the world’s fastest-growing energy resource. In North America, one megawatt of power can produce the energy needs for about 500 residential homes per year. By 2010, Canada expects to generate approximately 10,000 megawatts, while the world’s projected generation will be more than 100,000 megawatts.

Shear Wind’s exploration strategy is to identify land with strong and consistent wind energy potential and secure the surface rights. A comprehensive wind/energy output assessment program involving wind monitoring over 12 to 24 months is performed.

Phage therapy offers a safe and rapid solution

Biophage Pharma Inc. (TSX-V: BUG – News; “Biophage”) is pleased to provide an update on its integrated approach for the management of bacterial contamination in food produce. Both the biosensor and the phage therapy programs developed at Biophage are aimed at providing a safe and environmentally friendly solution for the control of deadly microorganisms in food produce (including meat, fruits and vegetable) like the recent case of E. coli 0157:H7 outbreak linked to bagged spinach in the US.

Since the E. coli O157:H7 outbreak in Walkerton, Ontario, where seven people died and a dozen more were hospitalized, Biophage has isolated a large number of bacteriophages against E. coli O157:H7 from water treatment plants and farms in the US and Canada. We presently have a large repertoire of specific phages for this deadly disease that could be developed as a powerful treatment for the control of E. coli O157:H7 bacterial contamination in food produce. Moreover, as complement to our strategy of management of bacterial contamination, our Biosensor technologies are also developed to be able to detect and identify live bacteria in a sample. These 2 technologies used together will allow the detection of pathogen and selection of the good treatment to apply for an efficient control of the bacterial contamination.

Dr Mandeville, President and CEO of Biophage commented, “Here at Biophage, we are ready to work with the government authorities to develop different strategies for the rapid containment of E. coli O157:H7 contamination in fresh produce”. Dr Mandeville continued, “Phage therapy is a safe and natural approach for the control of micro-organisms and Biophage is committed to develop and commercialize this anti-bacteria food safety solution”.

About Biophage Pharma Inc.
Biophage Pharma is a high potential, revenue-driven Canadian biotechnology company focused on the development of innovative phage-based technologies for the detection and management of live pathogens. Founded in 1995, Biophage Pharma has a well-advanced phage therapy program for the management of bacterial infections and has recently completed the development of its first prototype PDS(R) Biosensor which is entering in the pre-commercialization stage. Biophage also operates a profit center (Immunotox Labs) that provides services in Immunogenicity and Immunotoxicity, in Beryllium sensitivity testing and MELISA(R) testing for the detection of allergies to more than 20 different metals and a very large number of allergens like penicillin and pollens. (www.biophagepharma.com; www.immunotoxlabs.com).

For further information
Biophage Pharma Inc.: Rosemonde Mandeville, M.B., Ch.B., PhD President and CEO, (514) 496-1488, rosemonde.mandeville@biophagepharma.com
Renmark Financial Communications Inc.:
Christine Stewart: cstewart@renmarkfinancial.com
Ricardo Vallejos : rvallejos@renmarkfinancial.com
(514) 939-3989, Fax : (514) 939-3717, www.renmarkfinancial.com